Inflammatory profile
PreclinicalBiologic
Inflammatory profile is one of 25 biologic programs targeting Duchenne Muscular Dystrophy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Coreg
Akero TherapeuticsApproved
Advil
KKenvue Brands
Approved
Garamycin
SSchering-Plough
Approved
Rifadin
SanofiPhase 3
Duvyzat
ItalfarmacoPhase 3
Vyondys 53
Sarepta TherapeuticsApproved
Agamree
CCatalyst Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inflammatory profile. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- MMonica Levy Andersen